Compep: A biomarker to predict patients response to PI3K inhibitors

DESCRIPTION

Targeting PI3Ks appears to be a promising therapy in solid cancers. However there is a need for biomarkers to assess the selective PI3K isoform selective sensitivity.

A novel monoclonal antibody has been developed as a companion test to PI3K inhibitors in order to predict the patients response to treatment.

APPLICATIONS

Companion test for PI3K inhibitor drug for solid cancers as pancreas and lung cancer.